Repros Therapeutics — Investor Presentation (May 2014)
32 slides from Repros Therapeutics's investor presentation, May 13, 2014
Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai
Slide 3: Investment Highlights for 2014
Investment Highlights for 2014 Significant Value Creating Events for Androxal , An Oral Treatment for Low T Androxal Restores the Body’s ability to Produce Its Own Testosterone • Androxal ® 2014 Milestones – Complete all clinical studies – Complete head - to - head studies of Androxal versus Androge
Slide 4: Testosterone Market and Androxal Overview
Testosterone Market and Androxal Overview • US market for low testosterone exceeds $1.5 billion • Only approved non invasive therapies are hormone replacements • Repros believes 85% of hypogonadal men experience low T due to an endocrine disorder – These men have functional but un - stimulated teste
Slide 5: Who are the men using testosterone?
Who are the men using testosterone? European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng / dL LH:
Slide 6: Estrogen Exogenous Testosterone Override Suppresses LH and FSH
Estrogen Exogenous Testosterone Override Suppresses LH and FSH
Slide 7: Head to Head Comparison of Two Doses of Androxal to Testim and Placebo
Head to Head Comparison of Two Doses of Androxal to Testim and Placebo, Study ZA - 203 An approved T gel significantly suppresses LH and FSH in a clinically relevant manner and suppresses sperm concentration to near severe oligospermia (median sperm concentration 6.2 million/mL) after only three mon
Slide 8: Head to Head Studies Comparing Androxal to Androgel 1.62
Head to Head Studies Comparing Androxal to Androgel 1.62 Endpoints Changed per Late April FDA Guidance • ZA - 304 & ZA - 305: Two identical studies not under SPA – 3 arm parallel design with 40 subjects per arm – 23 US clinical sites – Primary endpoint comparison of Androxal and Androgel with respec
Slide 9: ZA-304 & ZA-305 Efficacy Endpoints
ZA - 304 & ZA - 305 Efficacy Endpoints Endpoint Class Endpoint Goal Powering Primary % of subjects with sperm concentration <10X10 6 /mL Comparing Androxal to Androgel 1.62% Show Androxal superior to Androgel 10% vs 50% 98.6% % change from baseline comparing Androxal to Androgel 1.62% Show Androxal
Slide 10: Testosterone Baseline Data Consistent with Study Inclusion/Exclusion Criteria
ZA - 304 & 305 Testosterone Baseline Data Consistent with Study Inclusion/Exclusion Criteria ZA - 305 Baseline Morning T (fully enrolled, n=127) Mean Age: 47 Mean BMI: 33.4 Morning T (ng/ dL ) Mean 216.2 Median 214.0 Standard Deviation 54.1 (Minimum, Maximum) (79.0,299.0) ZA - 304 Baseline Morning T
Slide 11: Sperm Baseline Data Consistent with Study Inclusion/Exclusion Criteria
ZA - 304 & 305 Sperm Baseline Data Consistent with Study Inclusion/Exclusion Criteria 0 2 4 6 8 10 12 14 16 18 20 22 24 <15 25 35 45 55 65 75 85 95 100 150 200 250 more Number of Subjects per Interval Mean Sperm Concentration (10 6 /mL) ZA - 305 Baseline Sperm Concentration Histogram 0 2 4 6 8 10 12
Slide 12: Median Semen Concentrations in ZA-203
Median Semen Concentrations in ZA - 203 Baseline 3 Months 1 Week Post Drug 4 Weeks Post Drug 12.5 mg 106.8 60.3 72.5 67.0 25 mg 66.0 47.0 98.8 64.0 Placebo 44.0 77.0 70.4 73.4 Testim 60.0 6.4 2.2 19.3 0.0 20.0 40.0 60.0 80.0 100.0 120.0 Sperm Concentration (million/mL)
Slide 13: ZA-203 Experience: % of Subjects Exhibiting >10 Million Sperm/mL
ZA - 203 Experience % of Subjects Exhibiting >10 Million Sperm/mL after 12 Weeks of Treatment 0 10 20 30 40 50 60 70 80 90 100 End of Study End of Study +1 week Placebo Androxal Testim p - values Androxal Testim Androxal EOS EOS+1 <0.0006 <0.001 Placebo EOS EOS+1 NS NS NS <0.0006 N=13 N=39 N=21 N=14
Slide 14: ZA-203 Experience: Median % Change from Baseline in Sperm Concentration
ZA - 203 Experience Median % Change from Baseline in Sperm Concentration after 12 Weeks of Treatment -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 Pacebo Androxal Testim End of Study End of Study +1 week p - value Androxal Testim Androxal EOS EOS +1 <0.0001 =0.006 Placebo EOS EOS +1 NS NS =0.018
Slide 15: Androxal Safety
Androxal Safety • Generally well tolerated at all doses – >1400 men exposed – >850 men for 6 months – >100 men for 12 months – >650 patient years of exposure • Adverse events consistent with increasing T – No exposure of T outside the normal range • Lower frequency of increased hematocrit 0 1 2 3 4
Slide 16: Excursions Above the Normal Range for T Leads to Increasing Hematocrit
Excursions Above the Normal Range for T Leads to Increasing Hematocrit with T Replacement “Exogenous testosterone (TT) is associated with physiologic changes that predispose to clotting and thrombotic disorders including increased blood pressure [18], polycythemia [19], reductions in HDL cholesterol
Slide 17: ZA-203 24 Hr Assessment Androgel 1%
ZA - 204 24 Hr Assessment Androgel 1% 0 500 1000 1500 2000 2500 3000 0 5 10 15 20 Total Testosterone Hours Some Subjects in Androgel Arm Exhibited T>1040
Slide 18: ZA-301 Study
ZA - 300 Study • 499 Subjects randomized – Baseline Morning T < 300 – 23.5% Type II Diabetes – 30.6% taking c holesterol medication – 33.3% previous T exposure • 6 months of treatment • 2 months of follow - up post treatment • 393 Subjects (78.8%) completed study – 23 (4.6%) Withdrew due to an Adver
Slide 19: Testosterone Response
Testosterone Response g Mean Morning Testosterone (NG/DL) 8 8 Baseline 6Weeks_-—«16 Weeks G Months 4 Weeks Post 8 Weeks Post Drug Drug.
Slide 20: ZA-301 Additional Findings after 6 months of treatment
ZA - 300 Additional Findings after 6 months of treatment • Androxal improves symptoms of metabolic syndrome – Androxal reduces total cholesterol and improves HDL/LDL ratio – Androxal reduces fasting plasma glucose levels – Androxal shifts A1c into normal range in a statistically significant manner •
Slide 21: Influence of Prior Testosterone
Influence of Prior Testosterone
Slide 22: Testosterone Replacement Induces Hormone Dependence in the Secondary Hypogonadal Male
ZA - 204 Testosterone Replacement Induces Hormone Dependence in the Secondary Hypogonadal Male in 6 Week Exposure Study 0 100 200 300 400 500 600 Baseline End of Study End of Study +1 Week Mean Morning Testosterone (ng/ dL ) Androxal Androgel N = 31 Mean =263 StDev =88.7 N = 14 Mean =248 StDev =74.2
Slide 23: ZA-300: Safety
ZA - 300: Safety • 499 subjects treated with Androxal – For up to 26 weeks • No new safety issues identified – No deaths – No significant cardiovascular findings – No significant eye findings • Venous Thromboembolism – One case (02 - 029) with deep vein thrombosis (DVT) and pulmonary emboli (PE), mu
Slide 24: Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement
Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Androxal Advantages – Oral – Not controlled substance, cannot be abused – Less CV risk than T’s??? • No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testi
Slide 25: Commercial Goals for Androxal
Commercial Goals for Androxal • Low T market already at primary care, 75% of written scripts • Specialists readily reached by Repros initiative – Conservative Quintiles assessment full year 1 sales = $120 million using small sales force (n=41) – Cash - flow positive during the first year of launch –
Slide 26: Proellex for the Treatment of Uterine Fibroids and Endometriosis
Proellex for the Treatment of Uterine Fibroids and Endometriosis • Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis • Over 300,000 hysterectomies performed every year in the US to treat these two disorders • No acceptable chronic therap
Slide 27: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone
Slide 28: Proellex Eliminates the Pain and Need for Analgesics in Endometriosis
Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline p - value versus placebo 25 mg = 0.001 50 mg = 0.017 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex %
Slide 29: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids
Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding and Bulk Symptoms Early Development Results 0 20 40 60 80 100 120 140 160 BL Mo 1 Mo 2 Mo 3 PBAC Score Pictorial Blood Loss Assessment Placebo Proellex 12.5 mg P<0.0001 0 5 10 15 20 25 30 35 40 45 Placebo Pro
Slide 30: ZPV-201 Ext. Proellex Open Label
ZPV - 200 Ext. Proellex Open Label 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12 mg vaginal dose shrinks fibroids significantly within 8 months of treatment
Slide 31: Proellex Program Status & Goals
Proellex Program Status & Goals • All Pre - clinical Studies Complete • 60 Subject Phase 2 Low Dose Oral Endometriosis Study Enrolling – Adding foreign sites – Expect full enrollment in the second half of 2014 • Phase 2 Low Dose Oral Fibroid Study Submitted to FDA – Full hold lifted to partial hold
Slide 32: Financial Summary
Financial Summary • Cash and equivalents (as of 3/31/14, unaudited) $68 M • Cash runway: Through 2016* – Anticipate Androxal approved and launched • Current shares outstanding: 23.1 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 809,805 @ $2.49 exer
Repros Therapeutics — Investor Presentation (May 2014) on 6ix